Sex hormones as an emerging weapon to combat COVID-19

Q. Mehmood, Priyanka Chahal, Parth A Patel, Prasant Upadhyay, Arisha Nawaz, Debraj Mukhopadhyay, A. Corriero, D. Mukherjee, Usman Garba Kurmi, Hadiza Abubakar Balkore, Vikas Jaiswal
{"title":"Sex hormones as an emerging weapon to combat COVID-19","authors":"Q. Mehmood, Priyanka Chahal, Parth A Patel, Prasant Upadhyay, Arisha Nawaz, Debraj Mukhopadhyay, A. Corriero, D. Mukherjee, Usman Garba Kurmi, Hadiza Abubakar Balkore, Vikas Jaiswal","doi":"10.31579/2640-1045/069","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019 and was declared pandemic by WHO in March 2020. The virus has been identified and named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel coronavirus strain is the causative agent of COVID-19, and continues to rapidly spread worldwide. SARS-CoV-2 is a highly pathogenic and transmissible coronavirus that spreads through respiratory droplets and unprotected close contact. “COVID‑19 outbreak, which has caused >95 million confirmed infections and >2 million coronavirus related deaths, is one of the most disastrous worldwide crises in recent years. Several methods have been used to examine SARS-CoV-2 infections.” i.e. RT-qPCR for viral RNA detection, and rapid screening procedures for antibody or virus detection. COVID-19 shows an incubation period of 3–7 days globally. Approximately 80% of the cases remain mild or asymptomatic, 15% are severe and 5% infectious cases turn to critical, requiring ventilation [2]. Several clinical trials have been proposed for its treatment and management with supportive aim of mortality reduction [1]. By glancing a view on fig 1, it can be evidently seen that COVID-19 cases have started to rise significantly since last few months. Furthermore, as per World Health Organization (WHO), there have been 131,020,967 confirmed cases of COVID-19 at a global level recently.","PeriodicalId":72909,"journal":{"name":"Endocrinology and disorders : open access","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology and disorders : open access","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31579/2640-1045/069","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019 and was declared pandemic by WHO in March 2020. The virus has been identified and named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel coronavirus strain is the causative agent of COVID-19, and continues to rapidly spread worldwide. SARS-CoV-2 is a highly pathogenic and transmissible coronavirus that spreads through respiratory droplets and unprotected close contact. “COVID‑19 outbreak, which has caused >95 million confirmed infections and >2 million coronavirus related deaths, is one of the most disastrous worldwide crises in recent years. Several methods have been used to examine SARS-CoV-2 infections.” i.e. RT-qPCR for viral RNA detection, and rapid screening procedures for antibody or virus detection. COVID-19 shows an incubation period of 3–7 days globally. Approximately 80% of the cases remain mild or asymptomatic, 15% are severe and 5% infectious cases turn to critical, requiring ventilation [2]. Several clinical trials have been proposed for its treatment and management with supportive aim of mortality reduction [1]. By glancing a view on fig 1, it can be evidently seen that COVID-19 cases have started to rise significantly since last few months. Furthermore, as per World Health Organization (WHO), there have been 131,020,967 confirmed cases of COVID-19 at a global level recently.
性激素是对抗COVID-19的新武器
2019冠状病毒病(新冠肺炎)于2019年在武汉开始流行,并于2020年3月被世界卫生组织宣布为大流行。该病毒已被确认并命名为严重急性呼吸综合征冠状病毒2型(严重急性呼吸系统综合征冠状病毒-2)。这种新型冠状病毒毒株是新冠肺炎的病原体,并继续在全球迅速传播。严重急性呼吸系统综合征冠状病毒2型是一种高致病性和传染性的冠状病毒,通过呼吸道飞沫和无保护的密切接触传播。“新冠肺炎疫情已导致9500多万确诊感染和200多万冠状病毒相关死亡,是近年来全球最灾难性的危机之一。已经使用了几种方法来检测严重急性呼吸系统综合征冠状病毒2型感染。”即用于病毒RNA检测的RT-qPCR,以及用于抗体或病毒检测的快速筛查程序。新冠肺炎的潜伏期为3-7 天。大约80%的病例仍为轻度或无症状,15%为重度,5%的感染病例转为危重病例,需要通气[2]。已经提出了几项临床试验来治疗和管理它,以降低死亡率为支持目标[1]。通过浏览图1,可以明显看出,自过去几个月以来,新冠肺炎病例开始显著上升。此外,根据世界卫生组织(世界卫生组织)的数据,最近全球共有131020967例新冠肺炎确诊病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信